Costas Lallas, MD
Urology · Philadelphia, PANPI 1922024090
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,980 of the $32,635 with a category attached, or 61.2%. 28 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 32.5% of the total. 2025 is the largest year on record at $21,749, more than ten times the $174 reported in 2019. Among urology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $274.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$11K
- Johnson & Johnson$10K
- Intuitive Surgical$8K
- Boston Scientific$840
- Telix Pharmaceuticals$570
- Teleflex LLC$299
- plus $2K from 22 others
Across 388 payments — averaging $9263.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.8M
- Medivation LLC.$1.8M
What the payments were for
- Consulting fees$19,98061%
- Speaking & faculty fees$5002%
- Travel & lodging$3,0969%
- Food & beverage$5,06016%
- Education$4,00012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 6 | $10,607 |
| Johnson & Johnson(2 entities) | 14 | $10,447 |
| Intuitive Surgical | 24 | $7,905 |
| Boston Scientific | 12 | $840 |
| Telix Pharmaceuticals | 9 | $570 |
| Teleflex LLC | 4 | $299 |
| Coloplast | 2 | $287 |
| Urogen Pharma, Inc. | 5 | $227 |
| Astellas Pharma US Inc | 8 | $184 |
| Rochester Medical Corporation | 4 | $154 |
| Palette Life Sciences, Inc. | 2 | $146 |
| Baxter Healthcare | 1 | $131 |
| AstraZeneca | 2 | $118 |
| Pfizer | 5 | $96 |
| Progenics Pharmaceuticals, Inc. | 3 | $86 |
| Photocure Inc | 3 | $75 |
| EDAP Technomed Inc | 1 | $68 |
| Sumitomo Pharma America, Inc. | 2 | $58 |
| Bayer | 2 | $54 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $54 |
| Convatec Inc. | 1 | $51 |
| Bluewind Medical | 1 | $39 |
| Myovant Sciences Inc. | 1 | $29 |
| Bioprotect Medical, Inc. | 1 | $28 |
| 180 Medical, Inc. | 1 | $25 |
| Merck | 1 | $21 |
| Astellas Pharma Global Development | 1 | $19 |
| Immunitybio, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,608
- ILLUCCIX$705
- Erleada$617
- TITAN$287
- UroLift$234
- PerClot$131
- GENERAL ERECTILE DYSFUNCTION$129
- Balversa$122
- AKEEGA$122
- SpaceOAR VUE System - 10mL$102
- LithoVue$100
How this compares
$32,635 in reported general payments places this provider in the 90th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 17 | $54,628 |
| MyrbetriqMirabegron | 17 | $20,203 |
| Tamsulosin Hcl | 133 | $2,516 |
| Finasteride | 73 | $948 |
| Tadalafil | 21 | $455 |
| Dutasteride | 20 | $425 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $228 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $58 | $54,62817 claims |
| Astellas Pharma US IncMyrbetriq | $184 | $20,20317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 urology providers in Pennsylvania.
Other urology in Philadelphia
- Demetrius BagleyPhiladelphia$739K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
- Paul ChungPhiladelphia$120K
- William JaffePhiladelphia$119K
- Robert UzzoPhiladelphia$111K
- Jay SimhanPhiladelphia$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.